Sarah Gaskell focuses her practice on the representation of clients in the health care and life sciences industries. She represents food, drug, and medical device manufacturers and hospitals, health systems, physician groups, and emerging digital health companies in complex regulatory, transactional, and compliance matters.
Sarah counsels life sciences clients on issues associated with clinical research and the regulation of food, drugs, and medical devices by the Food and Drug Administration (FDA), including product promotion and advertising, good manufacturing practices, product recalls, FDA inspections, and enforcement actions. She also provides regulatory and transactional due diligence support in life sciences M&A and other transactions.
Sarah's experience includes guiding clients through direct-to-consumer telemedicine, licensure, patient consent, remote supervision, and corporate practice of medicine issues. She also supports health care clients engaged in M&A and other strategic transactions, including physician practice and hospice acquisitions and private equity investments, and is involved in structuring various management service agreements and other arrangements to provide professional, management, or administrative services.
Sarah maintains an active pro bono practice, including serving as a guardian ad litem and representing clients in Section 1983 proceedings.
Sarah is a member of the Food and Drug Law Institute and the American Health Lawyers Association.
- The University of Chicago (J.D. 2020; Executive Editor, Chicago Journal of International Law); University of Dayton (B.A. magna cum laude 2009)
- District of Columbia and Massachusetts